Samsung Bioepis reported a slight year-over-year decline in operating profit for Q2 2026, driven by changes in supply schedules for key products and expanded research and development investment. The company disclosed on the 24th that Q2 consolidated revenue reached 392.2 billion won with operating profit of 86.6 billion won, down 2.2% and 3.6% respectively from the same period last year. Despite the quarterly dip, Samsung Bioepis expressed confidence that increasing product demand in major markets including Europe and the United States will sequentially reflect in second-half results, maintaining its commitment to sustained global business performance throughout the year.
Samsung Bioepis Reports Q2 2026 Financial Results
Samsung Bioepis announced Q2 2026 consolidated revenue of 392.2 billion won and operating profit of 86.6 billion won in a regulatory filing on the 24th. Revenue decreased 2.2% and operating profit fell 3.6% compared to the same quarter last year. The declines resulted from adjustments to supply schedules for major products and increased research and development spending.
For the first half of 2026, the company achieved revenue of 847.1 billion won and operating profit of 230.6 billion won, both representing 6% increases year-over-year.
Samsung Bioepis Expands Product Portfolio in Europe, US, and Japan
Samsung Bioepis launched an Eylea biosimilar in the European market in May, expanding its directly marketed products in the region to five. In the United States, the company began full-scale sales of a Prolia biosimilar, strengthening its position in key markets.
The company also expanded its global footprint by launching its first product in the Japanese market in May—a Stelara biosimilar.
Samsung Bioepis Discloses Keytruda Biosimilar Clinical Trial Results
Samsung Bioepis disclosed results from Phase 1 and Phase 3 clinical trials for its Keytruda biosimilar candidate SB27 in June. The company stated that the trials demonstrated equivalence to the original drug in the primary endpoints of pharmacokinetics (PK, the study of how the body processes a drug) in Phase 1 and efficacy in Phase 3.
In the antibody-drug conjugate (ADC) field, the new drug candidate SBE303 entered a global Phase 1 clinical trial targeting solid tumor patients in March. A second new drug candidate, SBE313, is currently in the preclinical stage.
Samsung Epis Holdings Records H1 2026 Performance
Parent company Samsung Epis Holdings achieved Q2 revenue of 391.9 billion won and operating profit of 58.8 billion won. For the first half of 2026, the holding company recorded revenue of 845.8 billion won and operating profit of 149.3 billion won.
Samsung Epis Holdings is building a stable business structure under its holding company system based on the solid performance of core subsidiary Samsung Bioepis. The company established its first overseas R&D hub in China in June to strengthen new drug development capabilities.
Samsung Epis Holdings Maintains Annual Revenue Growth Forecast
Samsung Epis Holdings maintained its forecast of over 10% annual revenue growth for Samsung Bioepis compared to the previous year's 1.672 trillion won, despite global market uncertainties.
FAQ
What were Samsung Bioepis's Q2 2026 financial results?
Samsung Bioepis reported Q2 2026 consolidated revenue of 392.2 billion won and operating profit of 86.6 billion won, representing year-over-year decreases of 2.2% and 3.6% respectively. The declines were attributed to changes in supply schedules for key products and expanded research and development investment.
What products did Samsung Bioepis launch in May?
In May, Samsung Bioepis launched an Eylea biosimilar in the European market, expanding its directly marketed products in Europe to five. The company also began full-scale sales of a Prolia biosimilar in the United States and launched its first product in Japan—a Stelara biosimilar.
What clinical trial results did Samsung Bioepis announce for its Keytruda biosimilar?
Samsung Bioepis disclosed in June that its Keytruda biosimilar candidate SB27 demonstrated equivalence to the original drug in Phase 1 and Phase 3 clinical trials. The trials met their primary endpoints of pharmacokinetics in Phase 1 and efficacy in Phase 3.
